NCT06750991View on ClinicalTrials.gov

CD-RCHOP in ND DLBCL With a Combination of TP53 Mutation and Del(17p)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2028

Conditions
DLBCL
Interventions
DRUG

CDR-CHOP

Rituximab 375 mg/m2 D1 Cyclophosphamide 750 mg/m2 D2 Doxorubicin 50 mg/m2 D2 Vincristine 1.4 mg/m2 D2 Prednisone 69 mg.m2 D2-6 Chidamide 20 mg/d D1,4,8,11 Decitabine 10 mg/m2 D-5 - -1

Trial Locations (1)

Unknown

No. 197 Ruijin 2nd Road, Huangpu District, Shanghai, Shanghai

All Listed Sponsors
lead

Ruijin Hospital

OTHER